CTMX Q2 2024 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$846M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M+1.6% YoY

Gross Profit

$25M100.0% margin

Operating Income

-$8M-33.7% margin

Net Income

-$7M-26.0% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

-39.4%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$159M

Total Liabilities

$190M

Stockholders' Equity

-$31M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$25M	+1.6%
Gross Profit	$25M	$23M	+8.3%
Operating Income	-$8M	-$3M	-152.4%
Net Income	-$7M	-$1M	-501.1%